Condensed interim consolidated financial statements of

PROMETIC LIFE SCIENCES INC.

For the quarter and nine months ended September 30, 2014

PROMETIC LIFE SCIENCES INC.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(In thousands of Canadian dollars) (Unaudited)

		September 30, 2014		December 31, 2013
ASSETS				
Current assets				
Cash	$	**10,383**	$	17,396
Accounts receivable (note 4)		**4,928**		14,172
Income tax receivable		**504**		-
Inventories (note 5)		**3,512**		2,979
Total cash generating current assets		**19,327**		34,547
Prepaid expenses		**817**		863
Total current assets		**20,144**		35,410
Restricted cash		**146**		139
Other investment		**29**		29
Capital assets (note 7)		**12,893**		9,631
Intangible assets (note 8)		**104,743**		4,663
Total assets	$	**137,955**	$	49,872
LIABILITIES AND EQUITY				
Current liabilities				
Accounts payable and accrued liabilities	$	**6,098**	$	7,877
Income tax payable		**56**		134
Debt provided by shareholders and other debt (note 9)		**-**		3,040
Advance on revenues from a supply agreement (note 10)		**3,667**		3,447
Total cash disbursing current liabilities		**9,821**		14,498
Deferred revenues (note 11)		**1,536**		984
Warrant liability (note 12)		**21,743**		9,311
Total current liabilities		**33,100**		24,793
Deferred tax liability		**39,800**		-
Long-term portion of lease inducement		**364**		224
Long-term debt (note 13)		**22,291**		6,217
Total liabilities	$	**95,555**	$	31,234
EQUITY				
Share capital (note 15)		**265,649**		263,320
Contributed surplus		**8,511**		6,319
Warrants		**13,261**		8,887
Future investment rights		**6,542**		6,542
Accumulated other comprehensive income		**248**		122
Deficit		**(264,354)**		(264,858)
Equity attributable to owners of the parent		**29,857**		20,332
Non-controlling interests (note 16)		**12,543**		(1,694)
Total equity		**42,400**		18,638
Total liabilities and equity	$	**137,955**	$	49,872

The accompanying notes are an integral part of the interim financial statements.

PROMETIC LIFE SCIENCES INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of Canadian dollars except for per share amounts) (Unaudited)

	Quarter ended September 30, 2014	Quarter ended September 30, 2013	Nine months ended September 30, 2014	Nine months ended September 30, 2013
Revenues (note 17)	**$ 2,315**	$ $5,960	**$ 12,464**	$ $15,566
Expenses (note 18)				
Cost of goods sold (note 5)	**867**	1,547	**4,659**	4,667
Research and development expenses recharged	**289**	1,780	**2,727**	5,391
Research and development expenses non-rechargeable	**7,557**	2,838	**20,670**	7,018
Administration and marketing expenses	**3,006**	1,981	**7,883**	4,570
Loss (gain) on foreign exchange	**26**	28	**10**	(426)
Loss on extinguishment of debt	**-**	-	**-**	423
Finance costs (note 18)	**774**	467	**1,825**	1,128
Fair value variation of warrant liability (note 12)	**10,420**	2,622	**12,432**	2,622
Loss in an associate (note 6)	**-**	-	**-**	69
Gain on revaluation of equity investment (note 6)	**-**	-	**(24,258)**	-
Purchase gain on business combination (note 3)	**-**	-	**(8,065)**	-
Net loss before income taxes	**(20,624)**	(5,303)	**(5,419)**	(9,896)
Income taxes - current	**53**	-	**500**	-
Net loss	**$ (20,677)**	$ (5,303)	**$ (5,919)**	$ (9,896)
Net loss attributable to:				
Owners of the parent	**(19,279)**	(5,257)	**(3,283)**	(9,479)
Non-controlling interests (note 16)	**(1,398)**	(46)	**(2,636)**	(417)
	$ (20,677)	$ (5,303)	**$ (5,919)**	$ (9,896)
Loss per share				
Basic and diluted loss per share attributable to the owners of the parent	**$ (0.04)**	$ (0.01)	**$ (0.01)**	$ (0.02)
Weighted average number of outstanding shares (in thousands)	**530,568**	491,174	**528,619**	487,184

The accompanying notes are an integral part of the interim financial statements.

PROMETIC LIFE SCIENCES INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands of Canadian dollars) (Unaudited)

	Quarter ended September 30,		Nine months ended September 30,	
	2014	2013	**2014**	2013
Net loss	**$ (20,677)**	$ (5,303)	**$ (5,919)**	$ (9,896)
Other comprehensive income (loss)				
Items that may be subsequently reclassified to profit and loss:				
Change in unrealized exchange differences on translation of financial statements of foreign subsidiaries	**28**	(37)	**126**	(51)
Total comprehensive loss	**$ (20,649)**	$ (5,340)	**$ (5,793)**	$ **(9,947)**
Total comprehensive loss attributable to:				
Owners of the parent	**(19,251)**	(5,294)	**(3,157)**	(9,530)
Non-controlling interests	**(1,398)**	(46)	**(2,636)**	(417)
	$ (20,649)	$ (5,340)	**$ (5,793)**	$ (9,947)

The accompanying notes are an integral part of the interim financial statements.

PROMETIC LIFE SCIENCES INC.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In thousands of Canadian dollars) (Unaudited)

	Share capital	Contributed surplus	Warrants	Future investment rights	Foreign currency translation reserve	Deficit	Total	Non-Controlling interests	Total equity
	$	$	$	$	$	$	$	$	$
Balance at January 1, 2013	234,563	3,216	8,546	6,542	207	(246,470)	6,604	(785)	5,819
Net loss	-	-	-	-	-	(9,479)	(9,479)	(417)	(9,896)
Foreign currency translation reserve	-	-	-	-	(51)	-	(51)	-	(51)
Share and warrant issue expenses	-	-	-	-	-	(28)	(28)	-	(28)
Share-based payments	-	465	-	-	-	-	465	-	465
Issuance of shares	3,848	(290)	(384)	-	-	-	3,174	-	3,174
Issuance of warrants	-	-	1,126	-	-	-	1,126	-	1,126
Balance at September 30, 2013	238,411	3,391	9,288	6,542	156	(255,977)	1,811	(1,202)	609
Balance at January 1, 2014	**263,320**	**6,319**	**8,887**	**6,542**	**122**	**(264,858)**	**20,332**	**(1,694)**	**18,638**
Net loss	**-**	**-**	**-**	**-**	**-**	**(3,283)**	**(3,283)**	**(2,636)**	**(5,919)**
Foreign currency translation reserve	**-**	**-**	**-**	**-**	**126**	**-**	**126**	**-**	**126**
Non-controlling interest arising from a business combination (note 3)	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**20,770**	**20,770**
Effect of changes in the ownership of a subsidiary and funding arrangements on non-controlling interest (note 16)	**-**	**-**	**-**	**-**	**-**	**3,897**	**3,897**	**(3,897)**	**-**
Share and warrant issue expenses	**-**	**-**	**-**	**-**	**-**	**(110)**	**(110)**	**-**	**(110)**
Share-based payments (note 15)	**-**	**2,599**	**-**	**-**	**-**	**-**	**2,599**	**-**	**2,599**
Exercise of options (note 15)	**554**	**(189)**	**-**	**-**	**-**	**-**	**365**	**-**	**365**
Shares issued pursuant to restricted share unit plan (note 15)	**218**	**(218)**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
Exercise of warrants (note 15)	**1,557**	**-**	**(805)**	**-**	**-**	**-**	**752**	**-**	**752**
Issuance of warrants	**-**	**-**	**5,179**	**-**	**-**	**-**	**5,179**	**-**	**5,179**
Balance at September 30, 2014	**265,649**	**8,511**	**13,261**	**6,542**	**248**	**(264,354)**	**29,857**	**12,543**	**42,400**

The accompanying notes are an integral part of the interim financial statements.

PROMETIC LIFE SCIENCES INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of Canadian dollars) (Unaudited)

Nine months ended September 30,		2014		2013
Cash flows used in operating activities				
Net loss for the period	$	**(5,919)**		(9,896)
Adjustments to reconcile net loss to cash flows used in operating activities				
Expenses paid with shares		**-**		6
Finance costs		**1,807**		716
Advance on revenues from a supply agreement		**-**		97
Loss on disposal of capital and intangible assets		**15**		35
Fair value variation of warrant liability		**12,432**		2,622
Gain on revaluation of equity investment (note 6)		**(24,258)**		-
Purchase gain on business combination (note 3)		**(8,065)**		-
Loss on extinguishment of debt		**-**		423
Share-based payments		**2,599**		465
Unrealized foreign exchange gain (loss)		**(7)**		38
Depreciation of capital assets (note 7)		**837**		228
Amortization intangible assets (note 8)		**351**		381
		(20,208)		(4,885)
Change in non-cash working capital items		**2,776**		(4,683)
	$	**(17,432)**	$	(9,568)
Cash flows from financing activities				
Proceeds from share and warrant issuances		**-**		11,349
Proceeds from debt and warrant issuances		**20,010**		10,010
Exercise of options		**365**		957
Exercise of warrants		**752**		-
Share and warrant issue expenses		**(338)**		(13)
Interest paid		**(48)**		66
Repayment of other debt		**(14)**		(457)
Repayment of debt provided by shareholders		**(3,550)**		(440)
Repayment of bank loan and other loan		**-**		(1,618)
	$	**17,177**	$	19,854
Cash flows used in investing activities				
Interest received		**246**		-
Additions to capital assets		**(6,052)**		(3,054)
Additions to intangible assets		**(894)**		(364)
	$	**(6,700)**	$	(3 418)
Net change in cash during the period		**(6,955)**		6,868
Net effect of currency exchange rate on cash		**(57)**		(48)
Cash, beginning of period		**17,395**		1,205
Cash, end of the period	**$**	**10,383**	$	8,025

The accompanying notes are an integral part of the interim financial statements.

1. Nature of operations

ProMetic Life Sciences Inc. ("ProMetic" or the "Corporation"), incorporated under the Canada Business Corporations Act, is a long-established, publicly traded (TSX symbol: PLI) (OTCQX symbol: PFSCF), biopharmaceutical Corporation with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic is focused on bringing safer, cost-effective and more convenient products to both existing and emerging markets. ProMetic offers its exclusive technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for efficient extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also active in developing its own novel small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, neutropenia, cancer, and autoimmune disease/inflammation as well as certain nephropathies.

The Corporation's head office is located at 440, Boul. Armand-Frappier, suite 300, Laval, Québec, Canada, H7V 4B4. ProMetic has Research and development ("R&D") facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and Canada and business development activities in the U.S., Europe and Asia.

2. Basis of presentation and accounting policies

a) Accounting framework

These unaudited condensed interim consolidated financial statements ("interim financial statements") for the quarter and nine months ended September 30, 2014 have been prepared in accordance with IAS 34, *Interim financial reporting*. Accordingly, certain information and footnote disclosure normally included in annual financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"), have been omitted or condensed. These interim financial statements should therefore be read in conjunction with the audited annual consolidated financial statements for the year ended December 31, 2013, which have been prepared in accordance with IFRS and which can be found at www.sedar.com.

These interim financial statements were approved for issue on November 11, 2014 by the Corporation's Board of Directors.

b) Changes in accounting policies

The accounting policies used in these interim financial statements are consistent with those applied by the Corporation in its December 31, 2013 audited annual consolidated financial statements, except for the following new interpretation adopted during the period:

IFRIC 21, *Levies*
IFRIC 21, *Levies* sets out the accounting for an obligation to pay a levy that is not income tax. The interpretation addresses what an obligating event is that gives rise to pay a levy and when should a liability be recognized. This interpretation is effective for annual periods beginning on or after January 1, 2014, and is applied retroactively. The adoption of this interpretation did not have a significant impact on the Corporation's interim financial statements.

c) New standards and interpretations not yet adopted

Standards and interpretations issued but not yet effective up to the date of the Corporation's consolidated financial statements are disclosed in the December 31, 2013 annual audited consolidated financial statements, except for the following listed below. The Corporation intends to adopt these standards when they become effective.

IFRS 15, *Revenue from contracts with customers*

In May 2014, the IASB issued IFRS 15, *Revenue from Contracts with Customers*, a new standard that specifies the steps and timing for issuers to recognize revenue as well as requiring them to provide more informative, relevant disclosures. IFRS 15 supersedes IAS 11, *Construction Contracts*, and IAS 18, *Revenue* and related interpretations. Adoption of IFRS 15 is mandatory and will be effective for the Corporation's fiscal years beginning on January 1, 2017, with earlier adoption permitted. The Corporation is currently assessing the impact of adopting this standard on its consolidated financial statements.

IFRS 9, *Financial Instruments – Recognition and Measurement*

In July 2014, the IASB issued the final version of IFRS 9, *Financial Instruments* with a mandatory effective date of January 1, 2018. The new standard brings together the classification and measurements, impairment and hedge accounting phases of the IASB's project to replace IAS 39*, Financial Instruments: Recognition and Measurement*. In addition to the new requirements for classification and measurement of financial assets, a new general hedge accounting model and other amendments issued in previous versions of IFRS 9, the standard also introduces new impairment requirements that are based on a forward-looking expected credit loss model. Management anticipates that the standard will be adopted in the consolidated financial statements for the annual period beginning January 1, 2018. The extent of the impact of the adoption of IFRS 9 has not yet been determined.

d) Significant accounting judgments and critical estimates

The preparation of these consolidated financial statements requires the use of judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. The uncertainty that is often inherent in estimates and assumptions could result in material adjustments to assets or liabilities affected in future periods. The significant accounting judgments and critical estimates applied by the Corporation are disclosed in its December 31, 2013 audited annual consolidated financial statements, except for the following disclosed below:

Determining whether assets acquired constitute a business – In determining whether the acquisition of an additional equity interest in NantPro BioSciences, LLC ("NantPro") (see note 3) fell within the scope of IFRS 3, *Business Combination*, management evaluated whether NantPro represented an integrated set of activities and assets capable of being conducted and managed for the purpose of providing a return in the form of dividends, lower cost or other economic benefits directly to investors or other owners, members or participants. Although NantPro is a development stage entity, management concluded that it had inputs, processes and other elements making it a business and therefore accounted for the acquisition as a business combination. If management had made a different determination, it would have accounted for the transaction as an asset acquisition and consequently the transaction would have been accounted for differently such as there would not have been a purchase price gain recorded in the consolidated statement of operations and the net asset acquired would have been recorded on a cost basis instead of fair value.

Assets arising from a business combination - The Corporation acquired a business in May 2014 (refer to note 3). The cost of the acquisition must be allocated to the underlying net assets acquired based on their estimated fair values calculated in accordance with the requirements of IFRS 3, *Business Combinations*. As NantPro assets consist of mainly intangible assets in the form of rights and licenses contributed by ProMetic when the partnership was created, the assets acquired generally represent reacquired rights. If during the determination of the fair value of the reacquired rights it is determined that the contracts giving rise to a reacquired right are favorable or unfavorable relative to the terms of current market transactions for the same or similar items, a settlement gain or loss will be recognized based on their respective estimated fair values.

As part of this allocation process, the Corporation must identify and attribute values and estimated lives to the identifiable assets acquired. These determinations involve significant estimates and assumptions regarding cash flow projections, the risk regarding the protein not being approved for sale, economic risk, weighted average cost of capital rates, expected market penetration, terminal values and manufacturing costs. These estimates and assumptions determine the amount allocated to the identifiable intangible assets, the amortization period for identifiable intangible assets with finite lives as well as settlement gains or losses recognized, if any, on reacquired rights. If future events or results differ adversely from these estimates and assumptions, the Corporation could record increased amortization or impairment charges in the future.

Determining the fair value of a business – In order to account for the business combination described in note 3, the Corporation must determine the value of the business acquired which in turn affects the values used in determining the fair value of the equity investment, an investment in an associate (at the acquisition date), the gain on revaluation of the equity investment, the purchase gain recognized on the business combination and the purchase price allocation. In determining the fair value of the business, the same significant estimates and assumptions as those involved in attributing values to the identifiable assets, discussed above are used. If different estimates and assumptions were made, the amounts recorded for intangibles assets, non-controlling interest, the purchase gain on a business combination and the gain on the revaluation of equity might have been significantly different.

3. Business combination

On May 8, 2014 ("date of acquisition"), the Corporation and NantPharma, LLC ("NantPharma") amended the terms of their partnership in NantPro BioSciences, LLC ("NantPro"). After a final payment of $857 (US$801,367), the remaining $6,607 (US$6,085,998) of accounts receivable due from NantPro to ProMetic, which normally would have been paid by NantPro with the NantPharma funding, was invested by ProMetic in order to obtain an additional 40.83% of equity units in NantPro. After consideration of the above investments by the partners, ProMetic owned 65.21% and NantPharma owned 34.79% of the equity units respectively on May 8, 2014. NantPro will be funded by ProMetic going forward and as a result, ProMetic will continue to acquire equity units in NantPro up to a maximum of 73%, while NantPharma's ownership may not be reduced below 27%. At September 30, 2014, the Corporation held 73% of the equity units of the partnership. Prior to date of the acquisition, the Corporation owned 30.47% of the NantPro units.

This issuance of units combined with the amendments to the terms of the partnership, including providing ProMetic with three out of five board seats, resulted in ProMetic obtaining control over NantPro, and NantPro being considered a subsidiary from the date of acquisition. ProMetic's former investment in an associate is deemed to have been disposed of for accounting purposes (refer to note 6 for the accounting impact of the revaluation of the equity investment). From May 8, 2014 onwards, the Corporation is consolidating the assets and liabilities of NantPro and its results of operations for the period subsequent to the change in control.

This transaction qualifies as a business combination and was accounted for using the acquisition method of accounting. To account for the transaction, the Corporation has performed a preliminary business valuation of NantPro at the date of acquisition and a preliminary purchase price allocation. These fair value assessment require management to make significant estimates and assumptions as well as applying judgment in selecting the appropriate valuation techniques. The collection, preparation and validation of this information as well as the conception of the valuation models involve a lot of effort. At the time of issuance of these financial statements, although a significant portion of this work has been performed, certain aspects of the valuation and purchase price allocation are not finalized. The amounts recognized during the quarter ended June 30, 2014 and during the nine months ended September 30, 2014 are therefore based on the preliminary results. The ultimate impact of this transaction may change from now until the final valuation report is received. The Corporation expects that this work will be completed by the end of 2014.

(In thousands of Canadian dollars) (Unaudited)

The Corporation recognised at the acquisition date all of the identifiable net assets of the partnership, the non-controlling interest in NantPro and a purchase gain on a business combination as follows:

Settlement of receivables for additional equity units	$	6,607
Acquisition date fair value of the previously held equity (note 6)		24,258
Total consideration		30,865
Net identifiable assets acquired:		
Intangible assets		99,500
Deferred tax liability		(39,800)
		59,700
Non-controlling interest		(20,770)
Net assets		38,930
Purchase gain on business combination	$	(8,065)

The Corporation elected to measure the non-controlling interest in NantPro using the proportionate share of its interest in NantPro's identifiable net assets as per applicable IFRS guidelines.

The parties to this transaction applied the terms of the partnership agreement which established the amount of funding required to acquire 1% of the partnership prior to the clinical trials phase. Consequently, ProMetic is acquiring additional interest in NantPro on the same basis as NantPharma was in the past, being 1% of ownership interest in NantPro for each US$131,579 of funding. This amount, determined when the partnership was established and unchanged since then, does not portray the fair value of a 1% interest in the business as of the transaction date resulting in a purchase gain.

The Corporation will be recognising NantPharma's, the non-controlling interest, share in the net assets and results of NantPro. Service revenues and research and development rechargeable expenses that other subsidiaries of ProMetic invoice to NantPro subsequent to May 8, 2014 will be eliminated upon consolidation. Certain materials, previously presented as inventories in the consolidated statement of financial position, will no longer generate product sales or service revenues on a consolidated basis and therefore no longer qualify to be presented as inventories. These inventories held as of the date of the transaction have been expensed in the consolidated statement of operation as research and development expenses non-rechargeable while future purchase of these materials will be expensed as those materials are received, regardless of whether they have been consumed.

4. Accounts receivable

		September 30, 2014		December 31, 2013
Trade	**$**	**1,691**	$	8,519
Loan to a Corporation, wholly-owned by an officer of the Corporation		**-**		3,015
Tax credits receivable		**2,389**		1,422
Sales taxes receivable		**485**		1,041
Advance to an officer		**51**		82
Other		**312**		93
	$	**4,928**	$	14,172

(In thousands of Canadian dollars) (Unaudited)

5. Inventories

	September 30, 2014	December 31, 2013
Raw materials	**$ 2,000**	$ 1,971
Work in progress and finished goods	**1,512**	1,008
	$ 3,512	$ 2,979

As a result of the NantPro BioSciences, LLC ("NantPro") business combination and the consolidation of NantPro as a subsidiary, inventories held by certain subsidiaries to perform rechargeable research and development services to NantPro when it was an associate no longer qualify to be presented as inventories as of May 8, 2014, the date NantPro is included in the consolidation perimeter. This is because on a consolidated basis, intercompany sales and revenues are eliminated and as such, the materials will not generate product sales nor rechargeable research and development revenues in the foreseeable future. As such, the cost pertaining to this inventory held as of the date of the transaction, in the amount of $1,379, was expensed in the consolidated statement of operations as research and development expenses non-rechargeable for the quarter ended June 30, 2014 while future purchase of these materials will be expensed as those materials are received, regardless of whether they have been consumed.

During the quarter and the nine months ended September 30, 2014, total inventories in the amount of $518 and $4,196 respectively ($1,463 and $4,453 for the quarter and the nine months ended September 30, 2013) were recognized as cost of goods sold.

6. Investment in an associate

On May 8, 2014, the Corporation and the other partner in the NantPro partnership, NantPharma, amended the partnership agreement and the Corporation increased its investment in NantPro. As a result of the amendment, the Corporation obtained control over Nantpro, and as of the acquisition date, its investment in NantPro represents an investment in a subsidiary. Further details regarding this transaction are provided in Note 3. For accounting purposes, the investment in the associate, 24.38% of NantPro's equity units at the transaction date, is deemed to have been disposed of on the date of change of control and is revaluated at fair value. Consequently, the Corporation has recognized a gain on revaluation of the equity investment of $24.3 million representing the difference between the fair value and the carrying amount ($Nil) of ProMetic's equity interest in NantPro just before the transaction. The gain has been determined based on a preliminary business valuation estimate and could be subject to change when the business valuation is finalized (refer to note 3 for details on the business valuation).

Up until May 8, 2014, the investment in NantPro was still accounted for as an investment in an associate and consequently the Corporation recognized revenues from the rendering of services to Nantpro of $ 3,665 for the nine months ended September 30, 2014 ($2,020 and $5,846 for the quarter and the nine months ended September 30, 2013). No revenues have been recorded since May 8, 2014.

(In thousands of Canadian dollars) (Unaudited)

The Corporation's share of the associate's losses and the net loss in the associate up to May 8, 2014 with the comparative figures, are as follows:

	Quarter ended September 30,		Nine months ended September 30,	
	2014	2013	**2014**	2013
Loss and comprehensive loss of an associate	**$ -**	$ (2,116)	**$ (3,811)**	$ (6,134)
The Corporation's share of the loss and comprehensive loss of the associate	**-**	(709)	**(1,161)**	(2,574)
Dilution gain	**-**	320	**195**	1,305
Net loss in an associate	**$ -**	$ (389)	**$ (966)**	$ (1,269)
Unrecorded portion of losses	**-**	389	**966**	1,200
Net loss in an associate recognized in consolidated financial statements	**$ -**	$ -	**$ -**	$ (69)

The accumulated balance of unrecorded losses at May 8, 2014 was $2,374 ($1,482 at December 31, 2013).

7. Capital assets

	Leasehold improvements	Production and laboratory equipment	Office equipment and furniture	Computer equipment	Total
	$	$	$	$	$
Cost					
Balance at January 1, 2014	5,946	7,951	717	605	15,219
Additions [1)]	1,678	2,184	74	138	4,074
Disposals	-	(8)	(5)	(4)	(17)
Effect of foreign exchange differences	65	58	5	5	133
Balance at September 30, 2014	**7,689**	**10,185**	**791**	**744**	**19,409**
Accumulated depreciation					
Balance at January 1, 2014	1,986	2,831	492	279	5,588
Depreciation charge	265	462	43	67	837
Disposals	-	(7)	(5)	(4)	(16)
Effect of foreign exchange differences	54	43	4	6	107
Balance at September 30, 2014	**2,305**	**3,329**	**534**	**348**	**6,516**
Carrying amounts					
At September 30, 2014	**5,384**	**6,856**	**257**	**396**	**12,893**
At December 31, 2013	3,960	5,120	225	326	9,631

[1)] As at September 30, 2014, included in additions to Production and laboratory equipment is $746 of production equipment under construction. The depreciation of these assets has not commenced since they are not considered to be available for use.

(In thousands of Canadian dollars) (Unaudited)

8. Intangible Assets

	Licenses	Patents	Software	Total
Cost	$	$	$	$
Balance at January 1, 2014	3,890	5,004	284	9,178
Additions	-	530	374	904
Acquired in a business combination [1)]	99,501	-	-	99,501
Disposals	-	(19)	-	(19)
Effect of foreign exchange differences	14	72	2	88
Balance at September 30, 2014	**103,405**	**5,587**	**660**	**109,652**
Accumulated amortization				
Balance at January 1, 2014	2,949	1,357	209	4,515
Amortization expense	62	265	24	351
Disposals	-	(3)	-	(3)
Effect of foreign exchange differences	26	20	-	46
Balance at September 30, 2014	**3,037**	**1,639**	**233**	**4,909**
Carrying amounts				
At September 30, 2014	**100,368**	**3,948**	**427**	**104,743**
At December 31, 2013	941	3,647	75	4,663

[1)] On May 8, 2014, the Corporation completed a business combination in which intangible assets, valued at $99.5 million based on a preliminary purchase price allocation, were acquired (refer to note 3 for further details). The intangible assets have an estimated useful life of 30 years. The amortization of these intangibles has not commenced since they are not considered to be available for use.

9. Debt provided by shareholders and other debt

The movement in the balance of the debt provided by shareholders and other debt is explained as follows:

Balance at January 1, 2014	$	3,040
Reimbursements		(3,564)
Interest		524
Balance at September 30, 2014	$	-

The principal amount of the debt provided by shareholders including interest, in the amount of $3,550 was reimbursed in August 2014.

10. Advance on revenues from a supply agreement

In 2009, the Corporation entered into a loan agreement with a customer whereby it received an advance on revenues relating to a supply agreement between the parties amounting to $3,400 (GBP 2,000,000). The advance bears interest at a rate of 5% per annum. The advance was being repaid as products were supplied and revenues received under the supply agreement, until both parties agreed to a moratorium on repayments. In May 2014, the Corporation and the customer amended the loan agreement, extending the maturity date until April 1, 2015.

(In thousands of Canadian dollars) (Unaudited)

11. Deferred revenues

		September 30, 2014		December 31, 2013
Deferred service revenues	**$**	**-**	$	228
Deferred product sales		**1,536**		756
	$	**1,536**	$	984

12. Warrant liability

The warrants issued in a financing transaction in September 2013, refered to as the "Second Warrants", give the holder the right to acquire common shares, the number of which is based on a formula, in exchange for $15,605 paid either in cash or in consideration of the lender's cancellation of the OID loan maturing on September 10, 2018. The Second Warrants expire on September 10, 2021, however the maturity period is shortened upon occurrence of a Market Capitalization Event whereby the market capitalization of the Corporation is greater than $1.5 billion for 60 consecutive days. If such an event was to occur before September 10, 2018, the Second Warrants would expire on September 10, 2018. If a Market Capitalization Event occurred after September 10, 2018, the warrants would expire within 90 days after the said event.

The Second warrants are presented in the consolidated statement of financial position as a liability, a derivative financial liability, which is required to be carried at fair value at each reporting date; the variations in fair value are recorded in the consolidated statement of operations in the period they occur. There is no future cash-payment associated with the recognized liability. However, if the warrants were to be exercised, the holder would have to pay the exercise price to the Corporation.

The fair value of the Second Warrants was estimated at $21,743 as of September 30, 2014 ($9,311 at December 31, 2013). The fair value of the warrant liability increased by $10,420 during the quarter ended September 30, 2014 and increased by $12,432 over the nine months ended on September 30, 2014, resulting in a loss of $10,420 and a loss of $12,432 for the respective periods.

The following assumptions were used in determining the fair value of the warrants on September 30, 2014: volatility 65%, marketability discount 35%, risk-free interest rates ranging from 1.8% to 2.3% over the potential life period of the warrants and an expected dividend rate of nil. The actual figures for the number of fully diluted shares outstanding was used as the estimated number of fully diluted shares over the warrants' life.

The effect of a change in the marketability discount and the volatility assumptions, which are the significant unobservable inputs used in the fair value estimate, by 10% at September 30, 2014 would have the following effect on the consolidated financial statements:

		Increase (decrease) in fair value of the warrant liability resulting from		
Assumption changed		a 10% increase		a 10% decrease
Volatility	$	653	$	(543)
Marketability discount		(545)		657

Concurrently with the July 31, 2014 debt modification described in note 13, the Corporation and the Second Warrant holder agreed to modify the terms of the Second Warrants. The objective of the modification is to replace the formula that was being used to determine the number of shares that would be issued upon exercise of the warrants with a fixed number of shares, since this formula, although it was allowing a potentially small variation in quantity, was causing the Second Warrants to be treated as a derivative liability. As a result of this treatment and the significant increase in the Corporation's share price since their issuance, a significant liability and significant losses have been recognized in the consolidated financial statements. Pursuant to the modification, the number of shares to be issued upon exercise would be fixed to 20,276,595 for an exercise price of $15,653.

(In thousands of Canadian dollars) (Unaudited)

The expiry date of the Second Warrants would remain unchanged at September 10, 2021 and the potential trigger to shorten the expiry date, the Market Capitalization Event, would be removed.

In accordance with the TSX rules, the modification must be approved by the Shareholders' of the Corporation before they become effective. In accordance with the terms of the agreement, these amendments must be approved no later than July 1, 2015 otherwise they will become null. Consequently, the Second Warrants will continue to be accounted for as a derivative liability until the amendments are approved. If and when these amendments become effective, the Second Warrants would cease to be a derivative liability and would become an equity instrument. The warrants would be recorded in equity at the fair value of the modified Second Warrants at the effective date.

13. Long-term debt

On July 31, 2014, the Corporation issued an Original Issue Discount ("OID") loan and warrants for total proceeds of $20,010. The total proceeds were allocated to the debt based on its fair value at the issue date and the residual amount was attributed to the warrants that are classified as equity. Further details concerning the warrants are provided in note 15. Under the terms of the loan, the Corporation will repay the face value of the OID loan, in the amount of $31,306 at maturity, on July 31, 2019. The loan is secured by all the assets of the Corporation excluding patents and requires that certain covenants be respected including maintaining an adjusted working capital ratio. The OID loan was recorded at its fair value at the transaction date less the associated transaction costs for a net amount of $14,713. The fair value of the loan was determined using a discounted cash flow model for the debt instrument with a market interest rate of 16.11%.

Concurrently, with the above transaction, the Corporation modified certain of the terms pertaining to the loan issued in September 2013. This loan has been modified from a loan with a principal of $10,000 bearing interest at a rate of 9% per annum, compounding monthly, to be paid on maturity of the loan together with the principal on September 10, 2018, to an OID loan having a face value of $15,653 maturing on the same date. Although the form of the debt instrument was amended together with certain of the terms, these adjustments are minor and essentially leave unchanged the cash flows of the previous loan agreement. These amendments were accounted for as a debt modification with no accounting impact to recognize on the date of the revised agreement. As well, the Corporation and the holder of the OID loans who in addition holds the Second Warrants also agreed to modify the terms of the Second Warrants. Further details regarding the proposed modifications are provided in note 12 – Warrant liability.

The carrying value of the long-term debt, at September 30, 2014, consists of the following:

		September 30, 2014		December 31, 2013
OID loan having a face value of $15,653 maturing on September 10, 2018	**$**	**7,190**	$	6,217
OID loan having a face value of $31,306 maturing on July 31, 2019		**15,101**		-
	$	**22,291**	$	6,217

(In thousands of Canadian dollars) (Unaudited)

14. Contractual obligations

The following table presents the contractual maturities of the financial liabilities, including operating leases as of September 30, 2014.

			Contractual Cash flows									
At September 30, 2014		**Carrying amount**		**Payable within 1 year**		**2 -3 years**		**4 -5 years**		**More than 5 years**		**Total**
Trade and other payables	$	6,154	$	6,154	$	-	$	-	$	-	$	6,154
Advance on revenues from a supply agreement		3,667		3,742		-		-		-		3,742
Long-term debt *		22,291		-		-		46,959		-		46,959
Operating leases		-		2,856		5,853		7,461		10,176		26,346
	$	32,112	$	12,752	$	5,853	$	54,420	$	10,176	$	83,201

* Under the terms of the long-term debt, the holder of Second and Third Warrants (see notes 12 and 15) may decide to cancel a portion of the face values of the OID loans as payment on the exercise of these warrants. The maximum repayment due on these loans has been included in the above table.

15. Share capital and other equity instruments

a) Share capital

Authorized and without par value:
Unlimited number of common shares, participating, carrying one vote per share, entitled to dividends.
Unlimited number of preferred shares, no par value, issuable in one or more series.

	September 30, 2014			September 30, 2013		
	Number		**Amount**	Number		Amount
Issued and fully paid common shares	**531,311,479**	**$**	**266,099**	493,359,143	$	238,861
Share purchase loan to an officer	**-**		**(450)**	-		(450)
Balance - end of period	**531,311,479**	**$**	**265,649**	493,359,143	$	238,411

Changes in the issued and outstanding common shares during the nine months ended September 30, 2014 and 2013 were as follows:

	September 30, 2014			September 30, 2013		
Issued and fully paid shares	**Number**		**Amount**	Number		Amount
Balance - beginning of period	**523,168,666**	**$**	**263,320**	432,531,873	$	224,741
Issued for cash	**-**		**-**	48,147,053		9,822
Issued in relation to debt renegotiation	**-**		**-**	1,043,476		490
Exercise of warrants	**4,652,587**		**1,557**	7,926,810		1,826
Exercise of options	**2,243,976**		**554**	2,934,038		1,248
Shares issued under restricted share units plan	**1,246,250**		**218**	-		-
Payment of expenses	**-**		**-**	775,893		284
Balance - end of period	**531,311,479**	**$**	**265,649**	493,359,143	$	238,411

(In thousands of Canadian dollars) (Unaudited)

b) Warrants and future investment rights ("rights")

The following table summarizes the changes in the number of warrants and rights outstanding during the nine months ended September 30, 2014 and 2013:

	September 30, 2014			September 30, 2013		
	Number		**Weighted average exercise price**	Number		Weighted average exercise price
Balance - beginning of period	**53,341,645**	**$**	**0.43**	62,487,763	$	0.38
Issued for cash	**16,723,807**		**1.87**	1,000,000		0.52
Issued in relation to debt renegotiation	**-**		**-**	754,715		0.53
Exercised	**(4,652,587)**		**0.16**	(7,926,810)		0.18
Balance - end of period	**65,412,865**	**$**	**0.82**	56,315,668	$	0.42

On July 31, 2014, the Corporation issued an original issue discount loan and warrants ("the Third Warrants") for an aggregate cash consideration of $20,010. Details regarding the loan issued are provided in note 13. As part of this financing transaction, the Corporation issued 16,723,807 Third Warrants, each giving the holder the right to acquire one common share at an exercise price of $1.87 paid either in cash or in consideration of the lender's cancellation of an equivalent amount of the face value of the OID loan maturing on July 31, 2019 (see note 13). The warrants expire on July 31, 2022. The value of the proceeds attributed to the Third Warrants was $5,179. The issuance costs related to the warrants, in the amount of $96, has been recorded in retained earnings.

During the nine months ended September 30, 2014, 4,652,587 warrants were exercised resulting in cash proceeds of $752 and a transfer from warrants to share capital of $805.

As at September 30, 2014, the following warrants and rights, classified as equity, to acquire shares were outstanding:

Number	Expiry date		Exercise price
2,142,855	February 2015	$	0.14
754,715	February 2015		0.53
44,791,488	February 2017		0.47
1,000,000	September 2021		0.52
16,723,807	July 2022		1.87
65,412,865		$	0.82

(In thousands of Canadian dollars) (Unaudited)

c) Share-based payments

Stock options

Changes in the number of stock options outstanding during the nine months ended September 30, 2014 and 2013 were as follows:

	September 30, 2014			September 30, 2013		
	Number		**Weighted average exercise price**	Number		Weighted average exercise price
Balance - beginning of period	**12,744,400**	**$**	**0.22**	12,274,538	$	0.19
Granted	**2,546,225**		**1.13**	3,915,000		0.36
Forfeited	**(64,500)**		**0.65**	(471,000)		0.25
Exercised	**(2,243,976)**		**0.16**	(2,934,038)		0.33
Expired	**(3,000)**		**0.13**	-		-
Balance - end of period	**12,979,149**	**$**	**0.40**	12,784,500	$	0.21

During the nine months ended September 30, 2014, 2,243,976 options were exercised resulting in cash proceeds of $365 and a transfer from contributed surplus to share capital of $189. The weighted average share price on the date of exercise of the options during the nine months ended September 30, 2014 was $1.30.

At September 30, 2014, options issued and outstanding by range of exercise price are as follows:

Range of exercise price	**Number outstanding**	**Weighted average remaining contractual life (in years)**		**Weighted average exercise price**	**Number exercisable**		**Weighted average exercise price**
$0.12 - $0.20	6,656,300	1.9	$	0.14	5,541,950	$	0.14
$0.21 - $0.88	3,781,124	3.6		0.38	2,026,255		0.35
$0.89 - $1.59	2,541,725	4.7		1.13	231,030		1.10
	12,979,149	2.9	$	0.40	7,799,235	$	0.23

The Corporation uses the Black-Scholes option pricing model to calculate the fair value of options at the date of grant. The weighted average inputs into the model and the resulting grant date fair values were as follows:

	September 30, 2014	September 30, 2013
Expected dividend rate	-	-
Expected volatility of share price	69.45%	89.22%
Risk-free interest rate	1.54%	1.30%
Expected life in years	4.6	5.0
Weighted average grant date fair value	$ 0.90	$ 0.25

A share-based payment compensation expense of $450 and $866 was recorded for the options for the quarter and the nine months ended September 30, 2014 ($252 and $465 for the quarter and the nine months ended September 30, 2013).

Restricted share units ("RSU")

During the quarter ended March 31, 2014, 1,246,250 vested RSU were released and an equivalent number of shares were issued out of treasury. During the quarter ended June 30, 2014, the Corporation granted 6,500,000 RSU to management (the "2014-2016 RSU"). The grant date fair value of a 2014-2016 RSU is $1.23. The RSU will only vest if the service and performance conditions set out are achieved. The expense is determined taking into account management's best estimate of whether or not the particular vesting conditions will be met as well as, in the case of those RSU that are expected to vest, the period it will take to meet the vesting requirements. These estimates are reviewed on an ongoing basis. A share-based payment compensation expense of $1,012 and $1,733 was recorded during the quarter and the nine months ended September 30, 2014 respectively.

(In thousands of Canadian dollars) (Unaudited)

A share-based compensation expense of $9 and NIL was recorded for the quarter and the nine months ended September 30, 2013. At September 30, 2014, 3,420,000 vested RSU and 6,500,000 unvested RSU were outstanding.

Share-based payment expense

The total share-based payment expense has been included in the interim consolidated statements of operations as indicated in the following table:

	Quarter ended September 30,		Nine months ended September 30,	
	2014	2013	**2014**	2013
Cost of goods sold	**$ 31**	$ 6	**$ 56**	$ 13
Research and development expenses recharged	**23**	23	**62**	55
Research and development expenses non-rechargeable	**358**	39	**669**	71
Administration and marketing expenses	**1,050**	194	**1,812**	326
	$ 1,462	$ 262	**$ 2,599**	$ 465

16. Non-controlling interests

The shares of three of the Corporation's subsidiaries are partially held by non-controlling interests. These are ProMetic BioProduction Inc. ("PBP"), Pathogen Removal and Diagnostic Technologies Inc. ("PRDT") and since May 8, 2014, NantPro (see note 3). The Corporation holds on September 30, 2014, 87.0%, 77.0% and 73.0% of the ownership interests respectively. The losses allocated to the non-controlling interests and the non-controlling interest balance on the consolidated statement of financial position, per subsidiary are as follows:

	September 30, 2014	December 31, 2013
In the consolidated statements of financial position		
PBP	**$ 157**	$ 1,041
PRDT	**(3,733)**	(2,735)
NantPro	**16,119**	-
Total non-controlling interests	**$ 12,543**	$ (1,694)

	Quarter ended September 30,		Nine months ended September 30,	
	2014	2013	**2014**	2013
In the consolidated statements of operations				
PBP	**$ (548)**	$ (92)	**$ (1,000)**	$ (180)
PRDT	**(415)**	46	**(883)**	(237)
NantPro	**(435)**	-	**(753)**	-
Total non-controlling interests	**$ (1,398)**	$ (46)	**$ (2,636)**	$ (417)

Between the date of acquisition of NantPro and September 30, 2014, the Corporation increased by 7.79% its interest in NantPro as a result of funding NantPro's activities and obtaining additional units during this period. The Corporation currently owns 73% of the equity units thus the maximum ownership it may acquire.

When the proportion of the equity held by non-controlling interests changes without resulting in a change of control, as is the case described above, the carrying amount of the controlling and non-controlling interest are adjusted to reflect the changes in their relative interests in the subsidiary. In these situations, the Corporation recognizes directly in equity the effect of the change in ownership of a subsidiary on the non-controlling interests. Similarly, after picking up its share of the operating losses, the non-controlling interest is adjusted for its share of the equity contribution made by ProMetic that does not modify the interest held by either party. The offset to this adjustment is recorded in the deficit. The effect of these transactions are presented in the statement of changes in equity for the nine months ended September 30, 2014.

(In thousands of Canadian dollars) (Unaudited)

17. Revenues

	Quarter ended September 30,		Nine months ended September 30,	
	2014	2013	**2014**	2013
Revenues from the sale of goods	**$ 1,029**	$ 2,235	**$ 7,330**	$ 6,770
Revenues from the rendering of services	**735**	2,190	**4,583**	7,261
Milestone and licensing revenues	**551**	1,535	**551**	1,535
	$ 2,315	$ 5,960	**$ 12,464**	$ 15,566

18. Information included in the interim consolidated statements of operations

	Quarter ended September 30,		Nine months ended September 30,	
	2014	2013	**2014**	2013
a) Government assistance included in research and development				
Gross research and development expenses	**$ 8,110**	$ 4,883	**$ 24,590**	$ 13,266
Research and development tax credits	**(264)**	(265)	**(1,193)**	(857)
	$ 7,846	$ 4,618	**$ 23,397**	$ 12,409
b) Finance costs				
Interest on long-term debt	**$ 773**	$ 385	**$ 2,006**	$ 971
Other interest expense, transaction and bank fees	**24**	82	**53**	157
Interest income	**(23)**	-	**(234)**	-
	$ 774	$ 467	**$ 1,825**	$ 1,128

19. Segmented information

The financial information is presented in two different operating segments, which are Therapeutics and Protein Technology.

Therapeutics: This operating segment has lead compounds, namely PBI-4050 which target unmet medical needs such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy.

Protein Technology: This operating segment contains the financial information of the following activities:

BioTherapeutics: The developer of a unique, validated, state-of-the-art solution for plasma fractionation, the Plasma Protein Purification System (PPPS™).

Bioseparation: Develops and markets bioseparation products based on applications of its patented Mimetic Ligand™ technology.

Prion Capture/Pathogen Removal: Provides a technology platform that improves the safety profile of blood products and blood-derived therapeutics.

The accounting policies for the operating segments are the same as those outlined in note 2. During the quarter ended September 30, 2014, ProMetic modified the presentation of the segmented information by reflecting in all three segments the allocation of administrative support expenses from the Corporate segment to the Therapeutics and Protein Technology segments, effectively mainly leaving in the Corporate segment the expenses pertaining to public entity reporting obligations, investor relations and other corporate office activities. This change has been applied retrospectively for all the periods presented.

The operating expenses for NantPro are included in the Protein Technology segment since May 8, 2014. When it was accounted for as an associate, the net loss in an associate was presented under the Corporate segment.

PROMETIC LIFE SCIENCES INC.
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
For the quarter and the nine months ended on September 30, 2014
(In thousands of Canadian dollars) (Unaudited)

a) Revenues and expenses by operating segments:

Quarter ended September 30, 2014	Therapeutics	Protein Technology	Corporate	Total
Revenues	$ 4	$ 2,311	$ -	$ 2,315
Cost of goods sold	-	867	-	867
Research and development expenses recharged	-	289	-	289
Research and development expenses non-rechargeable	1,321	6,236	-	7,557
Administration and marketing expenses	470	1,479	1,057	3,006
Loss (gain) on foreign exchange	(4)	348	(318)	26
Finance costs	13	45	716	774
Fair value variation of warrant liability	-	-	10,420	10,420
Net loss before income taxes	$ (1,796)	$ (6,953)	$ (11,875)	$ (20,624)

Nine months ended September 30, 2014	Therapeutics	Protein Technology	Corporate	Total
Revenues	$ 11	$ 12,453	$ -	$ 12,464
Cost of goods sold	-	4,659	-	4,659
Research and development expenses recharged	-	2,727	-	2,727
Research and development expenses non-rechargeable	3,781	16,889	-	20,670
Administration and marketing expenses	1,254	3,807	2,822	7,883
Loss (gain) on foreign exchange	(4)	348	(334)	10
Finance costs	18	131	1,676	1,825
Fair value variation of warrant liability	-	-	12,432	12,432
Gain on revaluation of equity instrument	-	(24,258)	-	(24,258)
Purchase gain on business combination	-	(8,065)	-	(8,065)
Net profit (loss) before income taxes	$ (5,038)	$ 16,215	$ (16,596)	$ (5,419)

Quarter ended September 30, 2013	Therapeutics	Protein Technology	Corporate	Total
Revenues	$ 2	$ 5,958	$ -	$ 5,960
Costs of goods sold	-	1,547	-	1,547
Research and development expenses recharged	-	1,780	-	1,780
Research and development expenses non-rechargeable	982	1,856	-	2,838
Administration and marketing expenses	504	999	477	1,980
Loss on foreign exchange	-	-	29	29
Finance costs	-	71	396	467
Fair value variation of warrant liability	-	-	2,622	2,622
Net loss before income taxes	$ (1,484)	$ (295)	$ (3,524)	$ (5,303)

(In thousands of Canadian dollars) (Unaudited)

Nine months ended September 30, 2013	Therapeutics	Protein Technology	Corporate	Total
Revenues	$ 10	$ 15,556	$ -	$ 15,566
Costs of goods sold	-	4,667	-	4,667
Research and development expenses recharged	-	5,391	-	5,391
Research and development expenses non-rechargeable	2,353	4,665	-	7,018
Administration and marketing expenses	1,229	2,174	1,167	4,570
Gain on foreign exchange	-	-	(426)	(426)
Loss on extinguishment of debt	-	-	423	423
Finance costs	-	193	935	1,128
Fair value variation of warrant liability	-	-	2,622	2,622
Loss in an associate	-	-	69	69
Net loss before income taxes	$ (3,572)	$ (1,534)	$ (4,790)	$ (9,896)

Segmented information by operating segment

b) Total assets by operating segment

	September 30, 2014	December 31, 2013
Therapeutics	**$ 1,925**	$ 3,157
Protein Technology	**126,117**	28,757
Corporate	**9,913**	17,958
	$ 137,955	$ 49,872

c) Capital and intangible assets by operating segment

	September 30, 2014	December 31, 2013
Therapeutics	**$ 171**	$ 2,160
Protein Technology	**116,734**	11,941
Corporate	**731**	193
	$ 117,636	$ 14,294

d) Acquisition of capital and intangible assets by operating segment

	Nine months ended September 30,	
	2014	2013
Therapeutics	**$ 466**	$ 403
Protein Technology [1)]	**103,681**	3,933
Corporate	**332**	114
	$ 104,479	$ 4,450

[1)] On May 8, 2014, the Corporation completed a business combination in which intangible assets, valued at $99.5 million based on a preliminary purchase price allocation, were acquired (refer to note 3 for further details).

(In thousands of Canadian dollars) (Unaudited)

e) Total liabilities by operating segment

		September 30, 2014		December 31, 2013
Therapeutics	$	**876**	$	597
Protein Technology		**49,283**		10,551
Corporate		**45,396**		20,086
	$	**95,555**	$	31,234

Information by geographic area

f) Total assets by geographic area

		September 30, 2014		December 31, 2013
Canada	$	**21,623**	$	30,491
United States		**102,448**		8,829
United Kingdom		**13,884**		10,552
	$	**137,955**	$	49,872

g) Capital and intangible assets by geographic area

		September 30, 2014		December 31, 2013
Canada	$	**9,557**	$	9,652
United States		**102,277**		2,312
United Kingdom		**5,802**		2,330
	$	**117,636**	$	14,294

h) Acquisition of capital and intangible assets by geographic area

		Nine months ended September 30,		
		2014		2013
Canada	$	**2,591**	$	3,481
United States		**100,197**		791
United Kingdom		**1,691**		178
	$	**104,479**	$	4,450

i) Revenues by location

		Quarter ended September 30,				Nine months ended September 30,		
		2014		2013		**2014**		2013
United States	$	**431**	$	3,594	$	**4,897**	$	8,719
Austria		**38**		2,025		**3,581**		5,303
Switzerland		**1,025**		88		**2,587**		898
Netherlands		**189**		66		**668**		76
Taiwan		**551**		-		**551**		-
United Kingdom		**40**		124		**60**		441
Other countries		**41**		63		**120**		129
	$	**2,315**	$	5,960	$	**12,464**	$	15,566

Revenues are attributed to countries based on the location of customers.

The Corporation derives significant revenues from certain customers. During the nine months ended September 30, 2014, there were two customers (one of them being NantPro) who accounted for 78% (29% and 49% respectively) of total revenues in the protein technologies segment. For the nine months ended September 30, 2013, there were two customers (one of them being NantPro) who accounted for 71% (38% and 33% respectively) of total revenues, also in the protein technologies segment.

20. Comparative information

Certain of the September 30, 2013 and the December 31, 2013 figures have been reclassified to conform to the current period's presentation.